Aclaris Therapeutics (ACRS) EPS (Basic) (2017 - 2025)
Historic EPS (Basic) for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$0.12.
- Aclaris Therapeutics' EPS (Basic) fell 909.09% to -$0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.58, marking a year-over-year decrease of 20384.62%. This contributed to the annual value of -$1.71 for FY2024, which is 3453.13% down from last year.
- Latest data reveals that Aclaris Therapeutics reported EPS (Basic) of -$0.12 as of Q3 2025, which was down 909.09% from -$0.13 recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' EPS (Basic) registered a high of -$0.02 during Q4 2023, and its lowest value of -$1.26 during Q4 2024.
- Its 5-year average for EPS (Basic) is -$0.33, with a median of -$0.31 in 2022.
- Its EPS (Basic) has fluctuated over the past 5 years, first surged by 9512.2% in 2023, then crashed by 621152.72% in 2024.
- Over the past 5 years, Aclaris Therapeutics' EPS (Basic) (Quarter) stood at -$0.37 in 2021, then fell by 10.81% to -$0.41 in 2022, then skyrocketed by 95.12% to -$0.02 in 2023, then tumbled by 6211.53% to -$1.26 in 2024, then skyrocketed by 90.49% to -$0.12 in 2025.
- Its EPS (Basic) was -$0.12 in Q3 2025, compared to -$0.13 in Q2 2025 and -$0.12 in Q1 2025.